European Society of Organ Transplantation Consensus Statement on Testing for Non-Invasive Diagnosis of Kidney Allograft Rejection

Sookhyeon Park,Joana Sellares,Claire Tinel,Dany Anglicheau,Oriol Bestard,John J. Friedewald

DOI: https://doi.org/10.3389/ti.2023.12115

2024-01-04

Transplant International

Abstract:To address the need for improved biomarkers for kidney transplant rejection, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in kidney transplant biomarkers to review literature pertaining to clinical and subclinical acute rejection to develop guidelines in the screening and diagnosis of acute rejection that were subsequently discussed and voted on during the Consensus Conference that took place in person in Prague. The findings and recommendations of the Working Group on Molecular Biomarkers of Kidney Transplant Rejection are presented in this article.

surgery,transplantation

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the improvement of non - invasive diagnostic methods for renal transplant rejection. Specifically, the European Society for Organ Transplantation (ESOT) organized a special working group consisting of experts in the field of renal transplant biomarkers, aiming to review the literature related to clinical and subclinical acute rejection and develop guidelines for screening and diagnosing acute rejection. These guidelines were discussed and determined by voting at the consensus conference held in Prague.

### Main Objectives:
1. **Improve the Sensitivity and Specificity of Biomarkers**: Currently, the monitoring of renal transplant rejection mainly relies on non - invasive measurement of serum creatinine levels and monitoring of immunosuppressive drug levels, but these methods are insensitive and lagging. Therefore, more sensitive and specific non - invasive monitoring tools are needed to reduce or eliminate the need for routine biopsies and guide biopsies when necessary.
2. **Provide Non - Invasive Diagnostic Tools**: Provide improved non - invasive tests for all renal transplant patients with normal function, especially within the first two years after transplantation, because the incidence of clinical and subclinical rejection is the highest during this period.
3. **Evaluate the Effectiveness of Existing Technologies**: Summarize the currently published evidence and evaluate the application of different non - invasive biomarkers (such as donor - derived cell - free DNA, gene expression profiles, urinary chemokines, etc.) in the diagnosis of renal transplant rejection.

### Key Questions:
- **Donor - Derived Cell - Free DNA (dd - cfDNA)**: In renal transplant patients with stable graft function, can dd - cfDNA be used as a reliable diagnostic tool for subclinical acute rejection?
- **Blood Gene Expression Profile (GEP)**: In renal transplant patients with stable graft function, can blood GEP be used as a reliable diagnostic tool for subclinical acute rejection?
- **Urinary Chemokines**: In renal transplant patients with stable graft function, can urinary chemokines (such as CXCL9 and CXCL10) be used as a reliable diagnostic tool for subclinical acute rejection?

### Recommendations:
- **dd - cfDNA**: It is recommended to use dd - cfDNA in patients with stable graft function to exclude subclinical antibody - mediated rejection.
- **GEP**: At present, blood GEP is not recommended for diagnosing or excluding subclinical rejection, and more prospective studies are needed to verify its value.
- **Urinary Chemokines**: It is recommended to monitor urinary CXCL9 and CXCL10 in stable patients to exclude subclinical rejection.

Through these guidelines, ESOT hopes to provide evidence - based recommendations for healthcare providers to improve the management and monitoring of renal transplant patients.